2014 Fiscal Year Final Research Report
Development of Lactobacillus-based therapeutic vaccine against Human papillomavirus for treatment of CIN3 patients
| Project/Area Number |
23592436
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
KAWANA kei 東京大学, 医学部附属病院, 准教授 (60311627)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | 子宮頸癌 / ヒトパピローマウイルス（HPV） / HPV分子標的がん免疫療法 / 粘膜免疫 / 経口ワクチン |
|---|
| Outline of Final Research Achievements |
Cervicalcancer and its precursor lesion,cervicalintraepithelial neoplasia grade3(CIN3)are a mucosal precancerous lesion caused by high-riskHPV.Induction ofimmunological clearance ofCIN3 by targetingHPV antigens is a strategy for CIN3therapy.We've evaluated the clinical efficacy of an attenuated Lactobacillus casei expressing HPV16E7,GLBL101c,in patients with HPV16-associatedCIN3.GLBL101c had a regression onCIN3to CIN2,but the efficacy remained partial.So we developed next generation E7-expressing Lactobacillus-basedvaccine to improve induction ofmucosalimmune responses to HPVE7.
1)TheJapanese herbalmedicines,JuzenTaihoTo(JTT)/HochuEkkiTo(HET)showed the synergy ofan oralLactobacillus-based vaccine on mucosalimmune responses.2)0.3μgofE7in1.2x10~8cells ofLactobacilluscasei wasthe most effective dose forimmunological inducibility with 2-fold higher thanthe existing,GLBL101c.The optimized newcancer-vaccine with increased pharmacologicaleffect will be a reliable drug for treatmentofCIN2-3.
|
| Free Research Field |
産婦人科学
|
